Results 1 to 10 of about 2,343,487 (194)
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
EMBO Molecular Medicine, 2019 Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains ...
Liping Ye +18 more
doaj +3 more sources
Molecular Therapy: Oncolytics, 2020 Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer.
Jun Zhou +9 more
doaj +3 more sources
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
Cells, 2021 Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic ...
Yu Cheon Kim +3 more
doaj +2 more sources
miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22 [PDF]
Cellular Physiology and Biochemistry, 2018 Background/Aims: Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.
Jun Li +5 more
doaj +2 more sources
Advanced Science, 2023 Tamoxifen is commonly used for the treatment of patients with estrogen receptor‐positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics.
Yao Tian +9 more
doaj +2 more sources
Frontiers in Oncology, 2022 Acquired resistance is a major clinical challenge for tamoxifen-based therapy. In this study, we focused on lncRNA SNHG6 which plays a role in chemoresistance of cancer cells, but has never been investigated in the context of tamoxifen resistance.
Mohammad Imran Khan +2 more
doaj +1 more source
Cancer Medicine, 2020 Tamoxifen‐based hormone therapy is central for the treatment of estrogen receptor positive (ER+) breast cancer. However, the acquired tamoxifen resistance, typically co‐exists with hypoxia, remains a major challenge.
Ying Li +10 more
doaj +1 more source
Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
Frontiers in Pharmacology, 2020 Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mechanism
Jingwei Yao +7 more
doaj +1 more source
Molecular Analysis of Acquired Tamoxifen Resistance in Breast Cancer Cell Line
Asian Pacific Journal of Cancer Biology, 2017 Background: Tamoxifen is an FDA approved drug for the prevention and the treatment of breast cancer, but its therapeutic benefit is limited by the development of drug resistance.
Mansour Abachi +4 more
doaj +3 more sources
Scientific Reports, 2020 Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh +3 more
doaj +1 more source